Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition · 31.07.2026
DOI: 10.1002/jpn3.70508 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 31.07.2026. Verfasst von Ross M Maltz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Infliximab, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit nennt 31 Literaturangaben. Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
To evaluate whether children with inflammatory bowel disease (IBD) who initiate infliximab originator versus biosimilar experience similar clinical outcomes at 12 months.
Methods
We conducted a retrospective cohort study evaluating prospectively collected data from the ImproveCareNow (ICN) Network registry. Children
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Division of Pediatric Gastroenterology, Michigan Medicine, Ann Arbor, Michigan, USA.
- Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Ross M Maltz
Förderung
- None
Zitieren
APA
Maltz, R. M., Adler, J., & ImproveCareNow Pediatric IBD Learning Health System (2026). Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70508
Vancouver
Maltz RM, Adler J, ImproveCareNow Pediatric IBD Learning Health System. Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70508
BibTeX
@article{Maltz2026,
author = {Maltz, Ross M and Adler, Jeremy and ImproveCareNow Pediatric IBD Learning Health System, ImproveCareNow Pediatric IBD Learning Health System},
title = {Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70508}
}
EUVIMED